Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery.

Pretorius M, Murray KT, Yu C, Byrne JG, Billings FT, Petracek MR, Greelish JP, Hoff SJ, Ball SK, Mishra V, Body SC, Brown NJ
Crit Care Med. 2012 40 (10): 2805-12

PMID: 22824930 · PMCID: PMC3588582 · DOI:10.1097/CCM.0b013e31825b8be2

OBJECTIVE - This study tested the hypothesis that interruption of the renin-angiotensin system with either an angiotensin-converting enzyme inhibitor or a mineralocorticoid receptor antagonist will decrease the prevalence of atrial fibrillation after cardiac surgery.

DESIGN - Randomized double-blind placebo-controlled study.

SETTING - University-affiliated hospitals.

PATIENTS - Four hundred forty-five adult patients in normal sinus rhythm undergoing elective cardiac surgery.

INTERVENTIONS - One week to 4 days prior to surgery, patients were randomized to treatment with placebo, ramipril (2.5 mg the first 3 days followed by 5 mg/day, with the dose reduced to 2.5 mg/day on the first postoperative day only), or spironolactone (25 mg/day).

MEASUREMENTS - The primary endpoint was the occurrence of electrocardiographically confirmed postoperative atrial fibrillation. Secondary endpoints included acute renal failure, hyperkalemia, the prevalence of hypotension, length of hospital stay, stroke, and death.

MAIN RESULTS - The prevalence of atrial fibrillation was 27.2% in the placebo group, 27.8% in the ramipril group, and 25.9% in the spironolactone group (p=.95). Patients in the ramipril (0.7%) or spironolactone (0.7%) group were less likely to develop acute renal failure than those randomized to placebo (5.4%, p=.006). Patients in the placebo group tended to be hospitalized longer than those in the ramipril or spironolactone group (6.8±8.2 days vs. 5.7±3.2 days and 5.8±3.4 days, respectively, p=.08 for the comparison of placebo vs. the active treatment groups using log-rank test). Compared with patients in the placebo group, patients in the spironolactone group were extubated sooner after surgery (576.4±761.5 mins vs. 1091.3±3067.3 mins, p=.04).

CONCLUSIONS - Neither angiotensin-converting enzyme inhibition nor mineralocorticoid receptor blockade decreased the primary outcome of postoperative atrial fibrillation. Treatment with an angiotensin-converting enzyme inhibitor or mineralocorticoid receptor antagonist was associated with decreased acute renal failure. Spironolactone use was also associated with a shorter duration of mechanical ventilation after surgery.

MeSH Terms (16)

Aged Angiotensin-Converting Enzyme Inhibitors Atrial Fibrillation Blood Pressure Cardiac Surgical Procedures Double-Blind Method Electrocardiography Female Hospitals, University Humans Male Middle Aged Ramipril Receptors, Mineralocorticoid Renin-Angiotensin System Spironolactone

Connections (3)

This publication is referenced by other Labnodes entities: